PITTSBURGH – A federal judge has granted a final opportunity to amend a class action complaint, for plaintiffs who claimed significant harm was sustained on behalf of themselves and/or their loved ones, based on a shortage of a pharmaceutical drug named Fabrazyme that began in 2009 and lasted until 2012.